Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pituitary Dwarfism Clear all
Completed Phase 2 Interventional Results available

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

NCT05250063
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
LUM-201
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 13 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Diego, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Completed No phase listed Observational

Adipose Tissue and Serum Inflammation in GH Deficiency

NCT03500913
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth Hormone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

NCT00675506
View directory record Official record
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 1Phase 2 Interventional

Versartis Trial in Children to Assess Long-Acting Growth Hormone

NCT01718041
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT01502124
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
21
States / cities
Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

NCT00182091
View directory record Official record
Conditions
Acromegaly, Growth Hormone Deficiency, Pituitary Disease
Interventions
Recombinant human growth hormone, Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

Role of Nutrition and Hormones in Boys With Disordered Growth

NCT00102258
View directory record Official record
Conditions
Short Stature, Constitutional Delay of Growth and Development, Dwarfism, Pituitary
Interventions
Growth Hormone Therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 4:49 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

NCT06948214
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
LUM-201, Matched Placebo (Capsules)
Drug · Other
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Madera, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
25
States / cities
Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 10, 2026, 4:49 AM EDT
Terminated No phase listed Observational

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

NCT00646308
View directory record Official record
Conditions
Growth Hormone Deficiency, Pituitary Tumor
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 10, 2026, 4:49 AM EDT
Not listed Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

NCT06007417
View directory record Official record
Conditions
GHD
Interventions
GenSci004, Genotropin
Drug
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 10, 2026, 4:49 AM EDT
Terminated Phase 4 Interventional Results available

Adult Growth Hormone Deficiency and Cardiovascular Risk

NCT00720902
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Blood draws, growth hormone releasing hormone (GHRH) & arginine, Carotid ultrasound, MRI, Endothelial cell biopsy
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
19 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

NCT02558829
View directory record Official record
Conditions
Growth Hormone Deficiency With Pituitary Anomalies
Interventions
Macimorelin, Insulin
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Torrance, California • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 10, 2026, 4:49 AM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Recruiting Phase 3 Interventional

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

NCT04867317
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions
Somatropin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 81 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 10, 2026, 4:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

NCT00235599
View directory record Official record
Conditions
Short Stature, Growth Hormone Deficiency
Interventions
IGFBP-3 Stimulation Test
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Sep 10, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

NCT05355272
View directory record Official record
Conditions
Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 10, 2026, 4:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle

NCT00004335
View directory record Official record
Conditions
Hypogonadism, Precocious Puberty
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
7 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1993
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

NCT00957671
View directory record Official record
Conditions
Growth Hormone Deficiency, Traumatic Brain Injury
Interventions
Recombinant human growth hormone
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 10, 2026, 4:49 AM EDT